Survival in sarcoidosis-associated pulmonary hypertension: The importance of hemodynamic evaluation

Chest

Volumn 138, Issue 5, 2010, Pages 1078-1085

  Baughman, Robert P ^a   Engel, Peter J ^b   Taylor, Lisa ^b   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b Ohio Heart and Vascular Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DYSPNEA; FEMALE; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SARCOIDOSIS;

EID: 78349285194     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-2002     Document Type: Article

References (34)

1. Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(2):108-116.
2. Rizzato G, Pezzano A, Sala G, et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis. 1983;64(2):121-128.
3. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008;32(2):296-302.
4. Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005;128(3):1483-1489.
5. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006;129(5):1246- 1252.
6. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006;61(1):68-74.
7. Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001;120(3):873-880.
8. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25(5):783-788.
9. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 2003;124(3):922-928.
10. Angomachalelis N, Hourzamanis A, Vamvalis C, Gavrielides A. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis. Postgrad Med J. 1992;68(suppl 1):S52-S56.
11. Yazaki Y, Isobe M, Hiroe M et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88(9):1006-1010.
12. Fahy GJ, Marwick T, McCreery CJ, Quigley PJ, Maurer BJ. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest. 1996;109(1):62-66.
13. Deng JC, Baughman RP, Lynch JPI III. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med. 2002;23(6):513-527.
14. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med. 2004;351(11):1097-1105.
15. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65-75.
16. Miyagishima K, Hiramitsu S, Kimura H, et al. Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction. Circ J. 2009;73(1):92-99.
17. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149-173.
18. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005;143(4):282-292.
19. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. BMJ. 1961;2(5261):1165-1172.
20. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-187.
21. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis. 1981;123(2):185-189.
22. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest. 2007;132(1):207-213.
23. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426-1435.
24. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax. 2009;64(10):883-888.
25. Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14(2):154-158.
26. Baughman RP, Shipley R, Desai S, et al; Sarcoidosis Investigators. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 2009;136(2):526-535.
27. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):189-194. (Pubitemid 40981192)
28. Corte TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(1):7-19.
29. Baughman RP, Lower EE. Therapy for sarcoidosis. European Respiratory Monograph. 2005;32:301-315.
30. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006;130(5):1481-1488.
31. Diaz-Guzman E, Farver C, Parambil J, Culver DA. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med. 2008;29(3):549-563., x.
32. Barnett CF, Bonura EJ, Nathan SD et al. Treatment of sarcoidosis- associated pulmonary hypertension: a two-center experience. Chest. 2009;135(6):1455-1461.
33. Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant. 2008;27(3):329-334.
34. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25(2):244-249.